Former CEO of evitria AG (2020-2023)
Mail: ce@evitria.com
Christian Eberle is a member of the Board of Directors of evitria’s parent company Atlas Antibodies and former CEO of evitria AG. He has led evitria AG through its growth trajectory from 2020 to 2023.
With both a Master’s degree in chemistry and a PhD in medicinal and pharmaceutical chemistry from ETH Zurich, he has brought profound expert knowledge into the operational level of biotechnology companies.
In the course of his career, Christian Eberle has accumulated broad experience in business strategy as well as in research, development and manufacturing within the pharmaceutical and biotechnology industry, but also in CDMO companies.
LinkedIn profile: Christian Eberle
Articles
Antibodies have been omnipresent in diagnostic and research domains for some decades now, and they are increasingly being utilized in the field of therapy. Their ability to bind to their target with incredible specificity and affinity has led to them being investigated and developed to become extremely important tools for research.
In recombinant antibody production, quality is of the essence. In order to manufacture high-quality – and, what’s obviously even more important – medically active compounds, the quality of the raw materials utilized needs to be top-notch. Learn why quality is so important and how the performance of antibodies can be improved.
This article will provide a comprehensive guide to polyclonal antibody production (pAb production), outlining the steps involved in the process, discussing the advantages and disadvantages of using polyclonal antibodies, and exploring the alternatives to polyclonal antibody production, including recombinant antibody production.